ライフサイエンスコーパス: peptide vaccine

1 timize the induction of CTL by a mucosal HIV peptide vaccine.

2 omly assigned to receive ipilimumab or gp100 peptide vaccine.

3 s virus T cell epitope to produce a chimeric peptide vaccine.

4 mor therapeutic activity of a tumor-specific peptide vaccine.

5 of low avidity, suggesting a Th1 response to peptide vaccine.

6 nological targets have led to more effective peptide vaccines.

7 ion of the peptide may enhance the effect of peptide vaccines.

8 d a number of early-phase clinical trials of peptide vaccines.

9 g to MHC in the rational design of synthetic peptide vaccines.

10 omplex (MHC)-presented antigens contained in peptide vaccines.

11 ne interface, could encompass effective MPER peptide vaccines.

12 e compared with existing MAGE-A3 protein and peptide vaccines.

13 well suited for the development of synthetic peptide vaccines.

14 transfer of mAbs is supplemented with cancer peptide vaccines.

15 and allogeneic tumour cell and WT1 analogue peptide vaccines.

16 ole antigens, which can be advantageous over peptide vaccines.

17 ors growing in situ, tumor cell lysates, and peptide vaccines.

18 to define the characteristics of efficacious peptide vaccines.

19 ven mutation can be induced or enhanced with peptide vaccines.

20 re a prerequisite to the design of effective peptide vaccines.

21 ations at 7-day intervals with the synthetic peptide vaccine (400, 800, or 1,600 mug per nostril) wit

22 Peptide vaccines able to induce high affinity and protec

23 a multi-adjuvant personalized synthetic long-peptide vaccine administered with nivolumab in patients

24 uating CD8(+) T cell-eliciting, HER2-derived peptide vaccines administered to HER2(+) breast cancer p

25 Administration of a potent, noninfectious peptide vaccine after adoptive cell therapy dramatically

26 in the development of an efficacious subunit peptide vaccine against equine infectious anemia virus (

27 represent potential candidates for use in a peptide vaccine against HTLV-1.

28 rant T cells in order to develop a synthetic peptide vaccine against T cells reactive with the aforem

29 1 transgenic mice (MUC1.Tg) i.v. with a MUC1 peptide vaccine against which they generate weak immunit

30 plicable to enhance the efficacy of DC-based peptide vaccines against cancer and other diseases.

31 identified might be potential components of peptide vaccines against NTHi.

32 targeting CD4 T cell responses directly with peptide vaccines against Salmonella can be effective in

33 ion and may improve CD8(+) T cell priming to peptide vaccines against viruses and cancer.

34 ial superagonist APLs to individualize tumor peptide vaccines among patients.

35 n antigen-specific immune response against a peptide vaccine and indicate that IL-12 may increase the

36 s the immunogenicity of an EGFRvIII-targeted peptide vaccine and to estimate the progression-free sur

37 MP increased CD8+ T cell responses primed by peptide vaccines and enhanced therapeutic antitumor immu

38 CTKAEL), has been used previously to produce peptide vaccines and was found to protect BALB/c mice ag

39 tion of the virus life cycle, development of peptide vaccines, and generation of gene delivery vector

40 DNA vaccines, dendritic-cell-based vaccines, peptide vaccines, and heat-shock protein vaccines.

41 dritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to

42 nized with a modified CALR(MUT) heteroclitic peptide vaccine approach.

43 cific CD8(+) T cells in aged mice, we used a peptide vaccine approach.

44 Variant peptide vaccines are used clinically to expand T cells t

45 Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved

46 The development of synthetic long-peptide vaccines avoids many of the pitfalls of previous

47 al antibodies and 'universal' preventive HPV peptide vaccine based on L1 conserved BCEs.

48 To improve the efficacy of a synthetic peptide vaccine based on the self-Ag, gp100, we sought t

49 Peptide vaccines based on such strategies may be worth t

50 Synthetic peptide vaccines based on the genes encoding cancer anti

51 efforts to develop recombinant or synthetic peptide vaccines based upon these high-molecular-weight

52 Here, we have adopted an immunotherapeutic peptide vaccine-based approach, to enhance the body's im

53 pharmacokinetically tuning the responses of peptide vaccines by fusing the peptide epitopes to carri

54 An experimental peptide vaccine called TMCP2 that mimics an oligosacchar

55 minary data suggest that this polyvalent WT1 peptide vaccine can be administered safely to patients w

56 A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to patients w

57 onclusion, a tumor-specific, bcr-abl derived peptide vaccine can be safely administered to patients w

58 Our results demonstrate that peptide vaccines can eradicate large, established tumors

59 Peptide vaccines can generate specific, highly protectiv

60 timize mucosal immune responses to the HIV-1 peptide vaccine candidate T1SP10 MN(A), we intranasally

61 ctive strategy for identifying peanut T-cell peptide vaccine candidates.

62 d within the framework of developing a pilin peptide vaccine capable of conferring broad immunity acr

63 thy adults support further evaluation of CMV peptide vaccines combined with PF03512676 in the HCT set

64 zed the CD8(+) T cell response to a NY-ESO-1 peptide vaccine composed of the two previously defined p

65 cases where cellular immunity was augmented, peptide vaccines composed of covalently linked minimal c

66 Two candidate CMV peptide vaccines composed of the HLA A*0201 pp65(495-503

67 SurVaxM is a peptide vaccine conjugate that has been shown to activat

68 We evaluated a single-vial peptide vaccine consisting of nine HLA-A2 supertype-bind

69 f such considerations, we developed a simple peptide vaccine construct that obviates immunodominance,

70 is the first demonstration in humans that a peptide vaccine containing minimal T and B cell epitopes

71 was derived from volunteers immunized with a peptide vaccine containing minimal T and B cell epitopes

72 Moreover, the use of peptide vaccines containing both CTLs and T helper epito

73 Peptide vaccines containing minimal epitopes of protecti

74 Design of biostable MHC I peptide vaccines containing unnatural subunits is desira

75 Here, we sought to determine whether a peptide vaccine could be developed using an epitope enha

76 and thus the protectiveness of a particular peptide vaccine could be related to its location in the

77 tumor efficacy of a human papilloma virus E7 peptide vaccine (CyaA-E7) capable of eradicating tumors

78 loring the potential of LCP NPs for use as a peptide vaccine delivery system for cancer therapy.

79 The NY-ESO-1 peptide vaccine elicited a CD8(+) T cell response direct

80 mmunosorbent assay (ELISA), each dose of the peptide vaccine elicited antipeptide serum IgA and IgG a

81 The peptide vaccine elicited serum IgG and intestinal IgA an

82 Peptide vaccine-elicited anti-V3 loop antibody responses

83 provided evidence that vaccinating with long peptide vaccines encompassing neoantigens can generate r

84 Peptide vaccines enhance the response of T cells toward

85 h serum and fecal antibodies elicited by the peptide vaccine exhibited neutralizing activity, as dete

86 Herein, we examined 5 different peptide vaccines following intraperitoneal injection, to

87 beneficial features for a PreS carrier-based peptide vaccine for birch pollen, which, in addition to

88 asis for the development of a hypoallergenic peptide vaccine for mugwort allergy.

89 ions of T cell specificity and the design of peptide vaccines for infectious disease and cancer using

90 itating the rational design of epitope-based peptide vaccines for malaria, as well as for other patho

91 he results of a number of clinical trials of peptide vaccines for melanoma, suggesting that immune an

92 upport the efficacy of DC-based, p53-derived peptide vaccines for the immunotherapy of cancer.

93 ify potential regions for the development of peptide vaccines for these viruses.

94 l immunogenicity, we tested a synthetic long peptide vaccine formulated with Montanide, poly-ICLC, an

95 ation vaccine incorporating J8-DT (conserved peptide vaccine from the M protein) and a recombinant Sp

96 A T-cell receptor (TCR) peptide vaccine from the V beta 5.2 sequence expressed i

97 ure work is geared toward the translation of peptide vaccines from preclinical to clinical utility.

98 tructures; large field trials of a synthetic peptide vaccine gave equivocal results.

99 Peptide vaccines generated from mitochondrial-encoded CO

100 e interleukin-2 plus the gp100:209-217(210M) peptide vaccine had a higher rate of response than the r

101 The 266-296 peptide vaccine had statistically reduced tumor onset in

102 nduce mucosal antibody in the rat to the GTF peptide vaccines HDS and HDS-GLU after intranasal admini

103 While peptide vaccines hold substantial promise in the prevent

104 s) play a pivotal role in the development of peptide vaccines, immuno-diagnostic reagents and antibod

105 ogenicity of a multidose, bcr-abl breakpoint peptide vaccine in 12 adults with chronic-phase CML.

106 e production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer.

107 protective capacity of the recombinant KEX1 peptide vaccine in a preclinical, nonhuman primate model

108 ) third variable region domain (V3) branched peptide vaccine in HIV-1-uninfected healthy adult volunt

109 e biomarkers were assessed with or without a peptide vaccine in ipilimumab-refractory and -naive mela

110 uating the safety and immunogenicity of P27A peptide vaccine in malaria-nonexposed European and malar

111 ity of a polyvalent Wilms tumor gene 1 (WT1) peptide vaccine in patients with acute myeloid leukemia

112 A new study of peptide vaccines in advanced renal cell carcinoma patien

113 esults may be relevant to the development of peptide vaccines in which a particular type of CTL respo

114 al immunization of macaques with a synthetic-peptide vaccine incorporating the LT(R192G) adjuvant.

115 Peptide vaccines incorporating structural elements commo

116 and we show that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes ind

117 in enhancing the antitumor effectiveness of peptide vaccines intended to elicit CTL responses.

118 ication of personalized neoantigen-targeting peptide vaccine is feasible and represents a promising p

119 hibitor observed in mice receiving CpG-based peptide vaccine is mainly dependent upon the use of CpG.

120 A synthetic peptide vaccine (J8-DT) from the conserved region of the

121 safety and efficacy of an H3.3K27M-targeted peptide vaccine.METHODSNewly diagnosed patients, aged 3-

122 Two chimeric peptide vaccines, MVF HER-2(316-339) and MVF HER-2(485-5

123 ccine-induced immunity and, because of this, peptide vaccines often contain epitopes designed to indu

124 We examined the effect of TCI with an HIV peptide vaccine on the induction of mucosal and systemic

125 Selective targeting of HylA using peptide vaccine or inhibitors alleviates acne pathology.

126 Immunization with the peptide vaccine or treatment with the B cell epitopes si

127 This study highlights how an endosomolytic peptide vaccine platform combined with two structurally

128 e, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses

129 dels and found that linkage to CPPs enhanced peptide vaccine potency in vivo by as much as 25-fold.

130 e approach that has been explored to enhance peptide vaccine potency is covalent conjugation of antig

131 rarectal immunization with the synthetic HIV peptide vaccine protected mice against infection via muc

132 However, the limited complexity of malaria peptide vaccines raises questions regarding their equiva

133 However, these peptide vaccines rarely result in efficient expansion of

134 Treatment with these mRNAs improved peptide vaccine responses and restored antitumour immuni

135 Variant peptide vaccine responses were also suppressed when AH1

136 binding prediction can greatly help clinical peptide vaccine search and design.

137 ly diverse effector CD4 TCR repertoires, but peptide vaccines skewed the memory CD4 TCR repertoire to

138 c epitopes may serve as candidates for novel peptide-vaccine strategies, and as tools to selectively

139 ng peptide-HLA (pHLA) binding is crucial for peptide vaccine target identification and epitope discov

140 ed a phase 1 clinical trial of a therapeutic peptide vaccine targeting DNAJ-PKAc (FLC-Vac), in combin

141 We conclude that a synthetic peptide vaccine targeting the LND would be a potentially

142 somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens.

143 4 years after treatment with NeoVax, a long-peptide vaccine targeting up to 20 personal neoantigens

144 Synthetic peptide vaccines targeting B-cell epitopes of the extrac

145 enterotoxin-mediated disease by design of a peptide vaccine that could reduce systemic exposure to o

146 cture and immunogenic properties of MPERp, a peptide vaccine that includes the following: (i) the com

147 Hence, we describe a two-component peptide vaccine that induces Abs (anti-S2) that protect

148 We designed a peptide vaccine that produces large numbers of tumor-rea

149 inin subunit 2 protein (HA2)-based synthetic peptide vaccine that provides protection in mice against

150 noma cells was used to design a heteroclitic peptide vaccine that successfully induced tumor protecti

151 However, peptide vaccines that include native tumor antigens rare

152 Our goal is to develop peptide vaccines that stimulate tumor antigen-specific T

153 nse by restimulation of T cells with the E75 peptide vaccine, thereby accounting for the improved dis

154 Personal neoantigen peptide vaccines thus induce T cell responses that persi

155 t may be possible to develop a pan-serotypic peptide vaccine to HRV, but its design will likely requi

156 ion, and to our knowledge, AE37 is the first peptide vaccine to show potency in the absence of an imm

157 We used a peptide vaccine to test the hypothesis that vaccine-elic

158 en administering powerful immunogens such as peptide vaccines to individuals who may have a large pre

159 ment of technologies that efficiently target peptide vaccines to secondary lymphoid tissues.

160 ance and steer immune responses to synthetic peptide vaccines toward selected functional types and to

161 edly found that two types of CpG-based tumor peptide vaccine treatments consistently negated the anti

162 d with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patient

163 based intranasal polylysine-linked synthetic peptide vaccine was effective in eliciting an adherence-

164 tective effect elicited by the TRP2(175-192) peptide vaccine was much weaker than that achieved by fu

165 lanoma, nivolumab at 3 mg/kg with or without peptide vaccine was well tolerated and induced responses

166 Vaccination with the helper peptide vaccine was well tolerated.

167 The peptide vaccines were immunogenic in both mice and rabbi

168 Although variant peptide vaccines were less effective as TAA expression i

169 ost animal tumor model systems used to study peptide vaccines were not truly representative of malign

170 ted an antigen-specific immune response to a peptide vaccine when combined with a human anti-CTLA-4 a

171 Synthetic peptide vaccines which are derived from functional domai

172 provide a basis for the development of novel peptide vaccines, whilst the expression of libraries of

173 Combining this E6/E7 peptide vaccine with checkpoint blockade produced only m

174 To improve current protocols, we combined peptide vaccines with mAb to the tyrosinase-related prot

175 The efficacy of a malaria peptide vaccine would be enhanced by the inclusion of a